Key facts
- Scipher Medicine’s last known valuation is $495.9M.
- It has raised $232.0M across 6 recorded rounds; the latest was Early Stage VC ($5.8M) in May 2024.
- Notable investors include Alumni Ventures, Khosla Ventures, Springboard Enterprises, Hitachi Ventures, Optum Ventures — 18 tracked in total.
- Scipher Medicine has filed 7 Form Ds with the SEC since 2018, most recently Jul 2024 ($5.8M sold to 1 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 6 rounds
- ·The complete investor list — 18 names
- ·Watchlist + deal alerts for Scipher Medicine
Funding rounds
6 roundsAbout Scipher Medicine
Developer of diagnostics and a precision medicine platform designed for therapy selection and drug development in autoimmune diseases. The company's platform integrates large-scale molecular interaction maps, a proprietary AI engine, and a growing clinico-genomic dataset to identify patient-specific disease signatures, enabling healthcare professionals to predict treatment response, stratify patients, and accelerate precision drug discovery with clinical accuracy and efficiency.
- Industry
- Discovery Tools (Healthcare)
- Sector
- Healthcare
- HQ
- Waltham, MA, United States
- Founded
- 2013
- Employees
- 61
- Website
- sciphermedicine.com/
- Ownership
- Privately Held (backing)
Scipher Medicine doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Scipher Medicine shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Scipher Medicine in its N-PORT filings yet. We sweep new filings monthly.